INT94543

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2001
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 0.96
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (MT2A) nucleus (MT2A) cytoplasm (MT2A)
Anatomy Link Frequency
MT2 3
bladder 1
bile 1
MT2A (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 60 99.12 Very High Very High Very High
Bile 9 98.64 Very High Very High Very High
interstitial cystitis 1 92.44 High High
Bioavailability 9 19.56 Low Low
GABAergic 24 5.00 Very Low Very Low Very Low
withdrawal 13 5.00 Very Low Very Low Very Low
Serotonin 12 5.00 Very Low Very Low Very Low
depression 9 5.00 Very Low Very Low Very Low
Inflammation 9 5.00 Very Low Very Low Very Low
addiction 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Bladder Cancer 9 94.40 High High
Bladder Disease 1 94.04 High High
Cystitis 3 92.96 High High
Toxicity 16 92.56 High High
Interstitial Cystitis 1 92.44 High High
Body Weight 1 81.84 Quite High
Carcinoma In Situ 1 75.84 Quite High
Argyria 56 63.20 Quite High
Cancer 6 58.80 Quite High
Sleep Initiation And Maintenance Disorders 72 50.00 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Immunohistochemical analysis disclosed no immunoreactivity for MT-1 and MT-2 (designated as MT-1/2 to reflect the nonspecificity of the antibody for the two isoforms) in cells comprising the normal bladder or in nonmalignant bladder disorders, such as cystitis and interstitial cystitis.
MT-2 Neg (no) Binding (immunoreactivity) of in bladder associated with cystitis, interstitial cystitis and bladder disease
1) Confidence 0.29 Published 2001 Journal Cancer Detect. Prev. Section Abstract Doc Link 11270423 Disease Relevance 0.72 Pain Relevance 0.09
This agonist developed by Eli Lilly also diplays a high affinity towards MT1 und MT2 receptors (Ki = 81 pM for MT1 bzw. 42 pM for MT2).
MT2 Binding (affinity) of in MT2 associated with agonist
2) Confidence 0.15 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05
This agonist developed by Eli Lilly also diplays a high affinity towards MT1 und MT2 receptors (Ki = 81 pM for MT1 bzw. 42 pM for MT2).
MT2 Binding (affinity) of in MT2 associated with agonist
3) Confidence 0.13 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05
The preferential binding to MT2 is typical for the 6-chlorinated melatonin derivatives, and also seen with 6-chloromelatonin.47 Because of the substitution at C-atom 6, this drug cannot be converted by the respective CYP isoforms to 6-hydroxymelatonin and its half-life in the circulation is, therefore, extended.47,62 Although ?
MT2 Binding (binding) of in MT2
4) Confidence 0.13 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2699659 Disease Relevance 0 Pain Relevance 0.05
As in other tissues, Ag+ evokes and binds MT-1 and MT-2 and is eliminated innocuously in bile without morphological change [101].
MT-2 Binding (binds) of in bile associated with bile
5) Confidence 0.04 Published 2010 Journal Advances in Pharmacological Sciences Section Body Doc Link PMC3003978 Disease Relevance 0.24 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox